Modelling the human immune response: Can mice be trusted?

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 431-435

  Gordon, John ^a   Grafton, Gillian ^a   Wood, Philip M ^a   Larché, Mark ^b   Armitage, Richard J ^c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c AMGEN INC   (United States)

Author keywords

Asthma; B cells; CD37; CD38; Eosinophils; Epstein Barr virus; Immunology; Interleukin 5; Molecular Medicine; Pharmacology; Species; Telomeres

Indexed keywords

ANIMAL; ASTHMA; B LYMPHOCYTE; BIOLOGICAL MODEL; DISEASE MODEL; HUMAN; IMMUNITY; IMMUNOLOGY; MOUSE; PHYSIOLOGY; REVIEW; SPECIES DIFFERENCE; TELOMERE;

ANIMALS; ASTHMA; B-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY; MICE; MODELS, BIOLOGICAL; SPECIES SPECIFICITY; TELOMERE;

EID: 0035433576     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00074-1     Document Type: Note

References (50)

1. Cho Y.G., Ramer J., Rivailler P., Quink C., Garber R.L., Beier D.R., Wang F. An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc Natl Acad Sci USA. 98:2001;1224-1229. Shows for the first time that Epstein-Barr-related viruses are not restricted to Old World monkeys.
2. Klein G. The Atheist and the Holy City. 1990;MIT Press, Cambridge, Massachusetts.
3. Crawford D.H. Biology and disease association of Epstein-Barr Virus. Philos Trans R Soc Lond B. 356:2001;1-13.
4. Crawford D.H. The Invisible Enemy: A Natural History of Viruses. 2000;Oxford University Press, Oxford. A highly readable and enjoyable book describing our continuous battle with viruses old and new.
5. Babcock G.J., Decker L.L., Volk M., Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity. 3:1998;395-404. An important paper showing that the natural lifelong reservoir of Epstein-Barr virus is the memory B lymphocyte.
6. Babcock G.J., Hochberg D., Thorley-Lawson D.A. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 13:2000;497-506.
7. Burrows P.D., Cooper M.D. B cell development and differentiation. Curr Opin Immunol. 9:1997;239-244.
8. Gaspar H.B., Conley M.E. Early B cell defects. Clin Exp Immunol. 119:2000;383-389.
9. Wicker L.S., Scher I. X-linked immunodeficiency (xid) of CBA/N mice. Curr Top Microbiol Immunol. 124:1986;87-101.
10. Minegishi Y., Rohrer J., Coustan-Smith E., Lederman H.M., Pappu R., Campana D., Chan A.C., Conley M.E. An essential role for BLNK in human B cell development. Science. 286:1999;1954-1957.
11. Pappu R., Cheng A.M., Li B., Gong Q., Chiu C., Griffin N., White M., Sleckman B.P., Chan A.C. Requirement for B cell linker protein (BLNK) in B cell development. Science. 286:1999;1949-1954.
12. Minegishi Y., Coustan-Smith E., Wang Y.H., Cooper M.D., Campana D., Conley M.E. Mutations in the human lambda5/14.1 gene results in B cell deficiency and agammaglobulinemia. J Exp Med. 187:1998;71-77.
13. Kitamura D., Kudo A., Schaal S., Muller W., Melchers F., Rajewsky K. A critical role for lambda 5 protein in B cell development. Cell. 69:1993;823-831.
14. von Freeden-Jeffry U., Vieira P., Lucian L.A., McNeil T., Burdach S.E., Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med. 181:1995;1519-1526.
15. Pribyl J.A.R., LeBien T.W. Interleukin 7 independent development of human B cells. Proc Natl Acad Sci USA. 93:1996;10348-10353.
16. Martin F., Kearney J.F. B1 cells: similarities and differences with other B cell subsets. Curr Opinion Immunol. 13:2001;195-201.
17. Wortis H.H., Berland R. Origins of B-1 cells. J Immunol. 166:2001;2163-2166. An elegant summary of current concepts on the origins of the B-1 subset of lymphocytes, as gleaned from murine studies.
18. Youinou P., Jamin C., Lydyard P.M. CD5 expression in human B cell populations. Immunol Today. 20:1999;312-316. An elegant summary of current concepts on the origins of the B-1 subset of lymphocytes, but from a human perspective.
19. Wortis H.H., Teutsch M., Higer M., Zheng J., Parker D.C. B cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. Proc Natl Acad Sci USA. 92:1995;3348-3352.
20. Gagro A., McCloskey N., Challa A., Holder M., Grafton G., Pound J.D., Gordon J. CD5-positive and CD5-negative B cells converge to an indistinguishable phenotype on signalling through B-cell receptors and CD40. Immunology. 101:2000;201-209. Shows that human B cells are very different in the way that CD5 and CD23 are regulated by exogenous signalling, when compared with their murine counterparts.
21. Lund F.E., Cockayne D.A., Randall T.D., Solvason N., Schuber F., Howard M.C. CD38: a new paradigm in lymphocyte activation and signal transduction. Immunol Rev. 161:1998;79-93.
22. McCloskey N., Pound J.D., Holder J., Williams J.M., Roberts L.M., Lord J.M., Gordon J. The extrafollicular-to-follicular transition of human B lymphocytes: induction of functional globotriaosylceramide (CD77) on high threshold occupancy of CD40. Eur J Immunol. 29:1999;3236-3244. The first time that the conditions for promoting the hallmark germinal centre B-cell antigen CD77 have been defined.
23. Oliver A.M., Martin F., Kearney J.F. Mouse CD38 is down-regulated on germinal center B cells and mature plasma cells. J Immunol. 158:1997;1108-1115.
24. L spare group I Burkitt lymphoma cells from CD77-directed killing via verotoxin-1 B chain but fail to protect against the holotoxin. Cell Death Differ. 7:2000;785-794. An important advance in defining the conditions under which Verotoxin-1 and its subunits can effect the killing of lymphoma cells.
25. Maloney M.D., Lingwood C.A. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med. 180:1994;191-201.
26. Katagiri Y.U., Mori T., Taguchi T., Takeda T., Kiyokawa N., Fujimoto J. Activation of Src family kinase Yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains. J Biol Chem. 274:1999;35278-35282.
27. Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., Regnault A., Desaymard C., Amigorena S., Ricciardi-Castagnoli P., et al. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC Class I-restricted presentation of peptides derived from exogenous antigens. J Immunol. 165:2000;3301-3308.
28. Kovacic N., Muthing J., Marusic A. Immunohistological and flow cytometric analysis of glycosphingolipid expression in mouse lymphoid tissues. J Histochem Cytochem. 48:2000;1677-1689. A comprehensive study of glycosphingolipid expression in mouse lymphoid tissues.
29. Hodes R.J. Telomere length, aging, and somatic cell turnover. J Exp Med. 190:1999;153-156.
30. Wright W.E., Shay J.W. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nat Med. 6:2000;849-851.
31. + T cell senescence in mice and men. Mech Ageing Dev. 121:2000;69-76. The title says it all!
32. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 183:1996;195-201.
33. Hamelmann E., Oshiba A., Loader J., Larsen G.L., Gleich G., Lee J., Gelfand E.W. Anti-interleukin 5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med. 155:1997;819-825.
34. Hogan S.P., Mould A., Kikutani H., Ramsay A.J., Foster P.S. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest. 99:1997;1329-1339.
35. Kaminuma O., Mori A., Ogawa K., Nakata A., Kikkawa H., Naito K., Suko M., Okudaira H. Successful transfer of late phase eosinophil infiltration in the lung by infusion of helper T cell clones. Am J Respir Cell Mol Biol. 16:1997;448-454.
36. Lefort J., Bachelet C.B., Leduc D., Vargaftig B.B. Effect of antigen provocation of IL-5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness. J Allergy Clin Immunol. 97:1996;788-799.
37. Malm-Erjefalt M., Persson C.G.A., Erjefalt J.S. Degranulation status of airway tissue eosiniphils in mouse models of allergic airway inflammation. Am J Respir Cell Mol Biol. 24:2001;352-359.
38. Eum S.Y., Hailet S., Lefort J., Huerre M., Vargaftig B.B. Eosinophil recruitment into the respiratory epithelium following antigenic challenge in hyper-IgE mice is accompanied by interleukin 5-dependent bronchial hyperresponsiveness. Proc Natl Acad Sci USA. 92:1995;12290-12294.
39. Korsgren M., Erjefalt J.S., Korsgren O., Sundler F., Persson C.G.A. Allergic eosinophil-rich inflammation develops in lungs and airways of B cell-deficient mice. J Exp Med. 185:1997;885-892.
40. Coyle A.J., Wagner K., Bertrand C., Tsuyuki S., Bews J., Heusser C. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med. 183:1996;1303-1310.
41. Brusselle G.G., Kips J.C., Tavernier J.H., van der Heyd J.G., Cuvelier C.A., Pauwels R.A., Bluethmann H. Attenuation of allergic airway inflammation in IL-4 deficient mice. Clin Exp Allergy. 24:1994;73-80.
42. Mehlhop P.D., van de Rijn M., Goldberg A.B., Brewer J., Kurup V.P., Martin T.R., Oettgen H.C. Allergen-induced bronchial hyperreactivity and eosinophilic inflammation occur in the absence of IgE in a mouse model of asthma. Proc Natl Acad Sci USA. 94:1997;1344-1349.
43. Robinson D.S., Ying S., Bentley A.M., Meng Q., North J., Durham S.R., Kay A.B., Hamid Q. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J Allergy Clin Immunol. 92:1993;397-403.
44. Humbert M., Durham S.R., Ying S., Kimmitt P., Barkans J., Assoufi B., Pfister R., Menz G., Robinson D.S., Kay A.B., Corrigan C.J. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 154:1996;1497-1504.
45. Hamelmann E., Vella A.T., Oshiba A., Kappler J.W., Marrack P., Gelfand E.W. Allergic airway sensitization induces T cell activation but not airway hyperresponsiveness in B cell-deficient mice. Proc Natl Acad Sci USA. 94:1997;1350-1355.
46. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., Mathur A.K., Cowley H.C., Chung K.F., Djukanovic R., et al. Effects of an interleukin 5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 356:2000;2144-2148. Shows that anti-IL5, proven to be so good for alleviating allergic symptoms in mouse models of asthma, may not be the wonder drug hoped for when it comes to people.
47. Pennisi E. A Mouse Chronology. Science. 288:2000;248-257.
48. Malakoff D. The rise of the mouse, biomedicine's model mammal. Science. 288:2000;248-253.
49. Harris R.F. Good news for mice! Curr Biol. 9:1999;R906.
50. Adams D. The Hitch Hiker's Guide to the Galaxy. 1979;Ballantine Books, London.